Nonsteroidal selective androgen receptor modulator · Fact sheet
RAD-140
Also known as RAD140 · Testolone
RAD-140 is an investigational SARM with early research in heavily pretreated breast-cancer patients. Liver-test abnormalities and treatment-related adverse events are central findings; the cancer study does not establish safe performance enhancement.
What is RAD-140?
RAD-140 activates androgen-receptor signaling and has been evaluated as an oncology drug.
A tolerable oncology dose under specialist monitoring is not a safe amount for a healthy athlete.
Benefits & claims
Interest includes performance or metabolic effects, but a mechanism, hormone change or lean-mass result does not establish safe improvement in athletic function.
What the evidence supports
- The trial demonstrated androgen-receptor engagement and preliminary tumor activity in a small selected population.
- The study was not designed to establish muscle gain, recovery or athletic function.
- Cell and animal neuroprotection findings cannot be converted into a human cognitive indication.
Research areas
- Performance-related biology
- Clinical or preclinical disease research
Dosage & frequency
No established human regimenThe reviewed sources do not establish a human treatment amount or frequency for RAD-140. Animal and laboratory exposures are not human regimens.
How to read these amounts
An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.
Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences
Formulations, interactions & practical context
- Identity and pharmacology
- RAD-140 activates androgen-receptor signaling and has been evaluated as an oncology drug.
Formulation differences
- A tolerable oncology dose under specialist monitoring is not a safe amount for a healthy athlete.
Interactions & precautions
- The reviewed sources do not establish a comprehensive human interaction profile for this exact substance or combination.
What is still unresolved
- Long-term clinically meaningful benefit
- Endocrine, cardiovascular and organ safety
- Identity, exposure and interaction differences outside research settings
Side effects & risks
- Elevated liver enzymes and bilirubin, vomiting, dehydration and other adverse events occurred in the cancer trial.
- Reports involving RAD-140-labeled products describe liver injury, with product identity and concurrent exposures complicating attribution.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research
Early human evidenceThe first-in-human trial enrolled 22 postmenopausal women with metastatic breast cancer. It was an uncontrolled dose-escalation study focused on safety and target engagement.
Studies
22-person phase 1 metastatic-breast-cancer study; important liver findings.
Liver-injury reports involving RAD-140 and combination-labeled products.
Personal experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.
No attributable personal accounts were found in the sources reviewed.
Approval status
RAD-140 has no FDA-approved therapeutic product. The cited research does not establish an approved performance-enhancement use.
Early human research; no FDA approval
Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.
Open questions
- Long-term clinically meaningful benefit
- Endocrine, cardiovascular and organ safety
- Identity, exposure and interaction differences outside research settings
Summary
Cell and animal neuroprotection findings cannot be converted into a human cognitive indication.
Sources
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- pubmedA First-in-Human Phase 1 Study of a Novel Selective Androgen Receptor Modulator (SARM), RAD140, in ER+/HER2- Metastatic Breast Cancer.
22-person phase 1 metastatic-breast-cancer study; important liver findings.
- pubmedDrug-Induced Liver Injury Associated With Alpha Bolic (RAD-140) and Alpha Elite (RAD-140 and LGD-4033).
Liver-injury reports involving RAD-140 and combination-labeled products.
- fdaFDA: serious risks of SARM bodybuilding products
FDA class-level warning: unapproved products, liver injury and cardiovascular and hormone-associated risks; not a compound-specific incidence estimate.